118 related articles for article (PubMed ID: 2955245)
41. Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity.
Paul ML; Currie RW; Robertson HA
Neuroscience; 1995 May; 66(2):347-59. PubMed ID: 7477877
[TBL] [Abstract][Full Text] [Related]
42. Forskolin potentiates the stimulation of rat striatal adenylate cyclase mediated by D-1 dopamine receptors, guanine nucleotides, and sodium fluoride.
Battaglia G; Norman AB; Hess EJ; Creese I
J Neurochem; 1986 Apr; 46(4):1180-5. PubMed ID: 3005508
[TBL] [Abstract][Full Text] [Related]
43. Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats.
Monti JM; Fernández M; Jantos H
Neuropsychopharmacology; 1990 Jun; 3(3):153-62. PubMed ID: 2141985
[TBL] [Abstract][Full Text] [Related]
44. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Lindgren HS; Ohlin KE; Cenci MA
Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
[TBL] [Abstract][Full Text] [Related]
45. 6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons.
Cole DG; Kobierski LA; Konradi C; Hyman SE
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9631-5. PubMed ID: 7937819
[TBL] [Abstract][Full Text] [Related]
46. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
Breese GR; Napier TC; Mueller RA
J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
[TBL] [Abstract][Full Text] [Related]
47. Excitatory and inhibitory dopaminergic regulation of oxytocin secretion in the lactating rat: evidence for respective mediation by D-1 and D-2 dopamine receptor subtypes.
Crowley WR; Parker SL; Armstrong WE; Wang W; Grosvenor CE
Neuroendocrinology; 1991 May; 53(5):493-502. PubMed ID: 1831247
[TBL] [Abstract][Full Text] [Related]
48. Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: evidence for D1 receptor involvement.
Calabresi P; Mercuri N; Stanzione P; Stefani A; Bernardi G
Neuroscience; 1987 Mar; 20(3):757-71. PubMed ID: 2955246
[TBL] [Abstract][Full Text] [Related]
49. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Biochem Pharmacol; 1995 May; 49(9):1185-93. PubMed ID: 7763300
[TBL] [Abstract][Full Text] [Related]
50. Activation of D1 receptors stimulates accumulation of gamma-aminobutyric acid in slices of the pars reticulata of 6-hydroxydopamine-lesioned rats.
Aceves J; Floran B; Martinez-Fong D; Benitez J; Sierra A; Flores G
Neurosci Lett; 1992 Sep; 145(1):40-2. PubMed ID: 1461565
[TBL] [Abstract][Full Text] [Related]
51. Differential effects of dopamine D-1 and D-2 agonists and antagonists in 6-hydroxydopamine-lesioned rats.
Arnt J
Psychopharmacology Suppl; 1985; 2():60-1. PubMed ID: 3159011
[No Abstract] [Full Text] [Related]
52. Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions.
Mango D; Bonito-Oliva A; Ledonne A; Nisticò R; Castelli V; Giorgi M; Sancesario G; Fisone G; Berretta N; Mercuri NB
Neuropharmacology; 2014 Jan; 76 Pt A():127-36. PubMed ID: 23973317
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
[TBL] [Abstract][Full Text] [Related]
54. Nigrostriatal lesion and dopamine agonists affect firing patterns of rodent entopeduncular nucleus neurons.
Ruskin DN; Bergstrom DA; Walters JR
J Neurophysiol; 2002 Jul; 88(1):487-96. PubMed ID: 12091570
[TBL] [Abstract][Full Text] [Related]
55. Different neuronal location of [3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in the rat.
Savasta M; Dubois A; Benavides J; Scatton B
Neurosci Lett; 1986 Dec; 72(3):265-71. PubMed ID: 2950341
[TBL] [Abstract][Full Text] [Related]
56. The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats.
Ushijima I; Mizuki Y; Yamada M
Psychopharmacology (Berl); 1988; 95(1):29-33. PubMed ID: 2898789
[TBL] [Abstract][Full Text] [Related]
57. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study.
Savasta M; Mennicken F; Chritin M; Abrous DN; Feuerstein C; Le Moal M; Herman JP
Neuroscience; 1992; 46(3):729-38. PubMed ID: 1532053
[TBL] [Abstract][Full Text] [Related]
58. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
Subramaniam S; Lucki I; McGonigle P
Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
[TBL] [Abstract][Full Text] [Related]
59. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
[TBL] [Abstract][Full Text] [Related]
60. A physiological role for dopamine as modulator of GABA effects in substantia nigra: supersensitivity in 6-hydroxydopamine-lesioned rats.
Waszczak BL; Walters JR
Eur J Pharmacol; 1984 Oct; 105(3-4):369-73. PubMed ID: 6439567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
